Compare Summit Therapeutics Inc (SMMT) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Summit Therapeutics Inc trades at $14.65 (market cap $10.48B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $32.34. Which is the better fit depends on your goals.
| SMMT | TMF | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $29.32 | $44.14 |
52-Week Low | $13.05 | $31.85 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $32.66, down 2.07% on the day, reflecting a bearish technical trend with moving averages signaling sell pressure. The fund provides 3x daily leveraged exposure to long-term U.S. Treasury bonds, making it highly sensitive to interest rate movements. Recent news highlights its significant long-term decline, with a $10,000 investment five years ago now worth approximately $1,527, underscoring the risks of daily leverage reset in volatile markets.
The outlook for TMF hinges on the direction of long-term bond yields and Federal Reserve policy. While some analysts see potential at the lower end of the trading range, the fund's structure makes it unsuitable for long-term holding due to volatility decay. Key risks include rising interest rates, inflation expectations, and the inherent leverage mechanism that amplifies losses. It remains a high-risk, tactical instrument for short-term traders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
